ArticleCardiovascular and interventional radiology2026
MARGIN: Randomized Trial of Arterial CT Portography Versus Standard Imaging Guidance for Percutaneous Thermal Ablation of Colorectal Liver Metastases.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05665322 (Translate Title), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Translate Title: Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases: Randomized, Single-blind, Controlled Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess whether arterial computed tomography portography guidance improves early local tumor control after percutaneous thermal ablation of small colorectal cancer liver metastases compared with standard-of-care imaging guidance, hypothesizing a ≥ 20% increase in complete ablation at 3 months confirmed by MRI and PET-CT. MATERIALS AND
methodsThis prospective, single-blind, two-center trial will randomize 88 adults (1:1) with up to three colorectal liver metastases ≤ 3 cm, including at least one not visible with ultrasound, to undergo ablation under either standard imaging guidance (intravenous contrast-enhanced CT, image fusion, or CT hepatic arteriography) or arterial portography after selective mesenteric or splenic catheterization in a hybrid angio-CT suite. Operators may use radiofrequency or microwave devices. The primary endpoint is complete ablation at 3 months on MRI and PET-CT. Secondary endpoints include lesion-level success, 12-month recurrence, safety, and a translational biobank. The sample size provides 80% power to detect a 20% absolute improvement (two-sided α = 0.05).
resultsNot applicable; protocol manuscript. EXPECTED GAIN OF KNOWLEDGE: The MARGIN trial will test whether arterial CT portography can improve complete ablation rates versus standard imaging in colorectal liver metastases. Beyond technical outcomes, it aims to refine image guidance strategies, optimize margin control, and generate high-level evidence for interventional oncology. The translational biobank will further link imaging findings to tumor biology and immune activation.
conclusionThis trial will test if arterial CT portography can improve early completeness of thermal ablation for colorectal liver metastases versus standard imaging.
trial registrationClinicalTrials.gov NCT05665322 (registered December 14, 2022). LEVEL OF EVIDENCE: Level 1b (randomized controlled trial).
Indexed as
Identifiers
41457158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.